top of page
ALKemistBio Logo.avif

Personalized Power: The End-to-End Path of Autologous T Cell Therapy

This autologous therapy not only offers a personalized solution to tumor heterogeneity and drug resistance but also holds promise for achieving longer-lasting remissions.

​By closing in on the ALK oncogene—often the molecular Achilles’ heel of these cancers—we aim to shift the paradigm from transient inhibition to immune-mediated eradication.

ALK+ cancer cell - ALKemist Bio.png

The patient’s own immune system becomes the cornerstone of a custom-engineered cancer therapy.

01

T Cell Collection

T cells are collected from the patient’s blood through leukapheresis, marking the first step in the development of a personalized therapy.

Paziente - ALKemist Bio2.png

T Cell Engineering

T cells are isolated and genetically modified via retroviral gene transfer to express a CAR or TCR capable of recognizing the ALK presented by tumor cells.

02

RVV - ALKemist Bio.png
T cell - ALKemist Bio.png
RVV - ALKemist Bio.png
T cell - ALKemist Bio.png
RVV - ALKemist Bio.png

03

Expansion of Engineered T Cells

After genetic modification, the ALK-specific T cells are expanded in vitro to obtain a sufficient number of functional cells for therapeutic use.

TCRT&CART - ALKemist Bio.png

Infusion into the Patient

The expanded ALK-specific T cells are infused back into the patient, marking the transition from laboratory to clinic.

04

Expansion of Engineered T Cells - ALKemist Bio_Tavola disegno 1.png

From lab to life: engineered T cells re-enter the body to seek out ALK-positive cancer cells.

05

Target Recognition and Tumor Cell Elimination

Once in the body, the engineered T cells identify and kill ALK-positive cancer cells by recognizing their specific antigens.

Phase 5 - ALKemist Bio.png

Back to the heart of it all.

bottom of page